Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15. SPC-15 is an intranasal 5-HT4 receptor agonist designed to treat post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. This allowance marks a significant expansion of the company's intellectual property portfolio, which already includes a recently granted European patent for the same core invention.
The Canadian patent application is held under an exclusive license from Columbia University, through which Silo has the rights to further develop, manufacture, and commercialize SPC-15 globally. This international protection is critical as Silo prepares to advance SPC-15 through clinical trials. The company intends to utilize the U.S. Food and Drug Administration's streamlined 505(b)(2) regulatory pathway, which could shorten clinical timelines and reduce development costs compared to traditional new drug applications. This pathway allows for reliance on existing data from published literature or prior approvals, potentially accelerating the route to market for this promising therapy.
The importance of this patent allowance cannot be overstated. PTSD affects millions of individuals worldwide, and current treatment options are often limited or associated with significant side effects. SPC-15 represents a novel approach, targeting the 5-HT4 receptor, which may offer a new mechanism of action for addressing this underserved condition. By securing intellectual property rights in key markets like Canada and Europe, Silo is positioning itself to capitalize on the commercial potential of SPC-15 while mitigating competitive risks.
Beyond SPC-15, Silo Pharma's pipeline includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to advance its research, such as the partnership with Columbia University that underlies the SPC-15 license. This collaborative approach not only enhances the scientific foundation of its programs but also strengthens its intellectual property estate.
The Canadian patent allowance is a testament to the novelty and inventiveness of SPC-15. It follows the recent grant of a European patent, indicating that the company's intellectual property strategy is gaining traction internationally. With corresponding applications advancing in other markets, Silo is building a robust global patent portfolio that will support its commercial ambitions.
For investors, this development signals that Silo is making tangible progress in securing the necessary protections for its lead asset. The use of the 505(b)(2) pathway could significantly reduce the time and cost to bring SPC-15 to market, potentially enhancing the return on investment. Moreover, the expansion into international markets opens up additional revenue opportunities.
As Silo continues to advance SPC-15 through the regulatory process, the company remains focused on addressing underserved medical needs in stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The Canadian patent allowance is a key milestone in this journey, reinforcing the company's commitment to innovation and patient care.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. To view the full press release, visit https://ibn.fm/L3Jm4.
